Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

[1]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[2]  L. Thomas,et al.  Second primary melanomas on treatment with vemurafenib , 2013, The British journal of dermatology.

[3]  J. Wolchok,et al.  Progression of RAS-mutant leukemia during RAF inhibitor treatment. , 2012, The New England journal of medicine.

[4]  Josep Malvehy,et al.  Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. , 2012, European journal of cancer.

[5]  J. Larkin,et al.  Treatment of brain metastases in patients with melanoma. , 2012, The Lancet. Oncology.

[6]  Suzanne Cheng,et al.  Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma , 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[7]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[8]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[9]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[10]  Chronic Disease Division.  Cancer facts and figures , 2010 .

[11]  M. Tucker,et al.  Increased risk of second primary cancers after a diagnosis of melanoma. , 2010, Archives of dermatology.

[12]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Donna Niedzwiecki,et al.  Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Gershuny,et al.  Central nervous system lnvolvement in malignant melanoma , 1988 .

[15]  Josep Malvehy,et al.  Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. , 2010, European journal of cancer.

[16]  A. Friedman,et al.  Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. , 1998, Journal of neurosurgery.